The clinical manifestations of hypogonadism in men are different from those of hypogonadism in women, which is marked by menopause. The clinical manifestations are diverse and may include decreased libido, erectile dysfunction, decreased ejaculation, loss of physical appearance, sensory weakness, decreased bone density, decreased muscle mass, increased body fat, fatigue and anemia, as well as cognitive function and sleep disturbances. A recent study published in the International Journal of Clinical Practice concluded that 38.7% of men over the age of 45 have hypogonadism. Because symptoms of aging and these diseases often overlap with those of hypogonadism, they are overlooked by most patients and clinicians. For androgen supplementation treatment of male hypogonadism, apart from oil injections, methyltestosterone used to be used orally, but it can affect liver function, so it has tended to be eliminated. In recent years, testosterone undecanoate has become the main drug for exogenous testosterone supplementation, and the dosage forms are oral and also patch absorbed from the skin, such as Stron, Antel, Anxiong and other products. Testosterone undecanoate, is an androgenic drug. As the undecanoate ester of testosterone, it is a testosterone derivative, which can promote male growth and development of paraphilias, and has a developmental effect on testes and paraphilias; it can promote protein synthesis and reduce catabolism; it can enhance immune function and promote bone growth; promote erythropoiesis and feedback inhibit sex hormone secretion. It is suitable for testosterone replacement therapy in male hypogonadal patients, for the treatment of post-orchiectomy, class azoospermia, hypopituitarism, endocrine erectile dysfunction, male menopausal symptoms (decreased libido, mental and physical strength, etc.), infertility due to certain c-spermatogenic dysfunctions, and aplastic anemia.